首页> 外文期刊>Pharmacoepidemiology and drug safety >Impact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS)
【24h】

Impact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS)

机译:基于人口的哮喘管理计划在法国(Sophia Asthme)的影响:使用法国健康保险数据库(SNDS)的匹配控制前后准实验研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Sophia Asthme (SA) is a chronic disease management program of the French national health insurance for adult patients with asthma. We evaluated the early impact of this intervention. Methods: We conducted a matched controlled, before-and-after quasi-experimental study within the French Health Insurance Database {Systeme National Des Donnees de Sante [SNDS]). The SA program was implemented in a set of 18 Departements in France and targeted 18- to 44-year-old subjects, with at least two reimbursement dates for asthma drug therapy during the 12-month period prior to program targeting. Change in outcomes was assessed from the "before program" period (January-December 2014) to the "after program implementation" period (March 2015-February 2016) in the program group (eligible to SA program in the 18 Departements) and in the matched controlled group. The main outcome measure was the before-after change in proportion of subjects with a controllers/(controllers +relievers) ratio greater than 50%. Results: Of the 99 578 subjects of the program group, 9225 (9.3%) actually participated in SA program. The program had no significant impact on the proportion of subjects with a ratio greater than 50%. However, subjects exposed to SA program were significantly more likely to be dispensed controller medications (OR = 1.04; 95% CI, 1.01-1.07) and to sustain their use of these medications (OR = 1.08; 95% CI, 1.05-1.12). Conclusion: We did not demonstrate any significant impact of the program on the primary outcome. The modest yet encouraging findings of this early evaluation suggest the need for reformulation of the program and its evaluation.
机译:目的:索菲亚Atthme(SA)是法国国家健康保险的慢性疾病管理计划,适用于哮喘的成人患者。我们评估了这种干预的早期影响。方法:我们在法国健康保险数据库内进行了一项匹配的控制,前后准实验研究{Systee National Des Donees de Sante [SNDS])。 SA计划在法国的一组18个部门实施,目标是18至44岁的受试者,在计划目标前12个月期间,至少有两项哮喘药物治疗的报销日期。从“计划”期间(2014年1月至2014年1月)期间(2016年3月)在计划集团(符合18个部门的SA计划)和在18个部门的SA计划)中,评估了结果的变更匹配的受控组。主要结果措施是在患有控制器/(控制器+ Religers)比例大于50%的受试者比例的前后变化。结果:99 578个计划组主题,9225(9.3%)实际参加了SA计划。该计划对比例的比例大于50%,对受试者的比例没有显着影响。然而,暴露于SA程序的受试者更容易被分配的控制器药物(或= 1.04; 95%CI,1.01-1.07),并维持它们对这些药物的使用(或= 1.08; 95%CI,1.05-1.12) 。结论:我们没有表现出对主要结果的任何重大影响。这种早期评估的适度但令人鼓舞的结果表明需要对该计划的重新制定及其评估。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号